On January 21, 2026 Defence Therapeutics Inc., ("Defence" or the "Company"), a publicly traded biotechnology company, reported an evolution of its corporate positioning to reflect its focus as a precision intracellular drug-delivery company advancing its proprietary Accum platform through both internal development programs and strategic partnerships. Designed to unlock the full potential of complex cancer biologics, Accum enhances intracellular delivery to increase therapeutic potency while reducing toxicity.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
At the center of this strategy is Accum, Defence Therapeutics’ proprietary precision drug-delivery platform designed to solve one of oncology’s most persistent challenges: effective intracellular delivery. By enhancing cellular uptake and payload release, Accum increases therapeutic potency at lower doses, with the potential to reduce toxicity and improve patient access to advanced cancer treatments.
Defence is prioritizing this platform and partnering model through a dual strategy that combines internal R&D programs with strategic partnerships across the biotech and pharmaceutical ecosystem. This approach enables the enhancement of both existing and next-generation assets, including antibody-drug conjugates (ADCs), radiopharmaceuticals, and other complex biologics, transforming therapies traditionally used in later lines into safer, more effective first-line treatment options.
"Our focus is clear: solve drug delivery at the cellular level so cancer therapies, whether developed by Defence or by our partners, can reach their full potential," said Sébastien Plouffe, CEO of Defence Therapeutics. "Accum is designed to create optimal value for partners while ultimately delivering better outcomes for patients."
With this refined positioning, Defence Therapeutics reinforces its commitment to precision oncology, collaboration, and translating cutting-edge science into life-changing treatments, with a business model designed to generate scalable value for partners and long-term value for shareholders.
(Press release, Defence Therapeutics, JAN 21, 2026, View Source;utm_medium=rss&utm_campaign=defence-therapeutics-sharpens-strategic-focus-on-precision-drug-delivery-to-unlock-the-full-potential-of-cancer-biologics [SID1234662128])